Fund Description: Tekla Life Sciences Investors, formerly H&Q Life Sciences Investors, is an exchange-traded closed-end fund or a closed-end ETF that is officially described as a diversified, closed-end management investment company. INVESTMENT OBJECTIVE: The Tekla Life Sciences Investors seeks to provide long-term capital appreciation. FUND STRATEGY: Under normal market conditions, the Fund expects to invest at least 80% of its net assets in securities of Life Sciences Companies. The Fund will not have less than 25% of its net assets invested in Life Sciences Companies. A company will be deemed to be a Life Sciences Company if, at the time the Trust makes an investment therein, 50% or more of such company's sales, earnings or assets arise from or are related to healthcare, agriculture or environmental management. The Fund may also invest in securities of companies that do not satisfy the above criteria but that are expected by the Investment Adviser to have 25% or more of sales, earnings or assets arising from or dedicated to healthcare, agriculture or environmental management, but investments in such securities will not count toward achieving the percentages mentioned above. The Investment Adviser determines, in its discretion, whether a company is a Life Sciences Company. The Trust may invest up to 25% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of U.S. issuers traded in foreign markets. FUND MANAGEMENT: Tekla Capital Management LLC serves as Investment Adviser to the Fund.